Definition of a Specialist Medicine
http://www.ipnsm.n-i.nhs.uk/library/RedAmberList.pdf
For the purposes of development of the Red/Amber list, a specialist medicine is defined as a medicine, which has significant pharmacological complexity and/or rarity of use to make the prescribing of the medicine relatively uncommon in the community. Patients for whom complex medicines are prescribed, may have particular complex monitoring requirements, which require specialist knowledge for the appropriate interpretation of results. In such circumstances, due consideration needs to be given to the settings and knowledge required by the professional to undertake the prescribing, monitoring and supply of the medicine, in order to ensure high quality patient care.
Red List The Red list is an advisory list where it is considered by the Regional Group, that responsibility for prescribing should remain with the consultant or specialist clinician. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy.
Amber List
The Amber list is an advisory list where it is considered by the Regional Group, that responsibility for prescribing may be transferred from secondary to primary care when agreed shared care arrangements have been established. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties. Appendix 1 provides an example of a template for development of a shared care guideline for Amber listed medicines. A shared care guideline details the respective clinical responsibilities of both parties. It is recommended that the development of a regional guideline for specific medicines or therapeutic group of medicines be facilitated by the Interface Pharmacist Network Specialist Medicines and developed in collaboration with consultants, GPs and others. Following endorsement by the Regional Group, the guidance could be adapted for local use with implementation being brought forward at local level through the Area Prescribing Forum in liaison with the Interface Pharmacist Network Specialist Medicines. A repository of regional guidelines will be held on the IPNSM website.
Amber Sub Group
Medicines which fall under this category, while not falling within the definition of a ‘specialist medicine’, may cause particular monitoring difficulties for GPs. Individual Boards should have local flexibility in deciding whether these require a shared care agreement.
http://www.ipnsm.n-i.nhs.uk/library/RedAmberList.pdf
For the purposes of development of the Red/Amber list, a specialist medicine is defined as a medicine, which has significant pharmacological complexity and/or rarity of use to make the prescribing of the medicine relatively uncommon in the community. Patients for whom complex medicines are prescribed, may have particular complex monitoring requirements, which require specialist knowledge for the appropriate interpretation of results. In such circumstances, due consideration needs to be given to the settings and knowledge required by the professional to undertake the prescribing, monitoring and supply of the medicine, in order to ensure high quality patient care.
Red List The Red list is an advisory list where it is considered by the Regional Group, that responsibility for prescribing should remain with the consultant or specialist clinician. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy.
Amber List
The Amber list is an advisory list where it is considered by the Regional Group, that responsibility for prescribing may be transferred from secondary to primary care when agreed shared care arrangements have been established. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties. Appendix 1 provides an example of a template for development of a shared care guideline for Amber listed medicines. A shared care guideline details the respective clinical responsibilities of both parties. It is recommended that the development of a regional guideline for specific medicines or therapeutic group of medicines be facilitated by the Interface Pharmacist Network Specialist Medicines and developed in collaboration with consultants, GPs and others. Following endorsement by the Regional Group, the guidance could be adapted for local use with implementation being brought forward at local level through the Area Prescribing Forum in liaison with the Interface Pharmacist Network Specialist Medicines. A repository of regional guidelines will be held on the IPNSM website.
Amber Sub Group
Medicines which fall under this category, while not falling within the definition of a ‘specialist medicine’, may cause particular monitoring difficulties for GPs. Individual Boards should have local flexibility in deciding whether these require a shared care agreement.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.